The therapeutic landscape for Immunoglobulin A Nephropathy (IgAN)—also known as Berger’s disease—is undergoing a massive shift. For decades, treatment was largely limited to managing symptoms with optimized supportive care, such as ACE inhibitors or ARBs. Now, disease-modifying biologics are taking center stage.

Sibeprenlimab (development code: VIS649, now approved under the brand name VOYXACT®) has emerged as a frontrunner in this space. By directly targeting the underlying immune pathogenesis of IgAN, it offers researchers and clinicians a powerful new tool to halt progressive kidney damage.

Here is everything researchers need to know about the structural profile, mechanism of action (MoA), manufacturer details, and the latest clinical data for Sibeprenlimab.

Sibeprenlimab is a biologic therapy meticulously engineered to interrupt the specific autoimmune cascade that drives IgA Nephropathy.

• The Molecule: Sibeprenlimab is a humanized Immunoglobulin G2 (IgG2) monoclonal antibody.
• The Target: It selectively binds to and neutralizes APRIL (A PRoliferation-Inducing Ligand, also known as TNFSF13), a cytokine belonging to the tumor necrosis factor (TNF) superfamily.
• Developers: The molecule was originally designed and engineered using proprietary computational technology by Visterra, Inc., a Boston-based biotechnology company. Visterra is a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., who is leading the global commercialization and late-stage clinical development of the drug.
• Administration: It is formulated as a 400 mg subcutaneous injection intended for administration every four weeks.

To understand Sibeprenlimab’s efficacy, researchers must look at the universally recognized "4-hit hypothesis" of IgAN pathogenesis. Sibeprenlimab specifically intervenes at the critical first step of this cascade:

1. Hit 1 (The Root Cause): In IgAN, patients produce abnormal, poorly glycosylated IgA1 antibodies, known as galactose-deficient IgA1 (Gd-IgA1). The survival of the B-cells and plasma cells that produce this pathogenic Gd-IgA1 is heavily dependent on the cytokine APRIL.
2. APRIL Inhibition: Sibeprenlimab acts as an APRIL-neutralizing antibody. By binding to APRIL, it prevents the cytokine from interacting with its receptors (TACI and BCMA) on B-cells.
3. Halting the Cascade: Without APRIL stimulation, the production of Gd-IgA1 drops dramatically. Consequently, there is less substrate for autoantibodies to bind to (Hit 2), preventing the formation of circulating immune complexes (Hit 3).
4. Kidney Preservation: With fewer immune complexes forming, the downstream deposition of these complexes into the glomerular mesangium of the kidney (Hit 4) is drastically reduced. This prevents the subsequent inflammation, hematuria, proteinuria, and irreversible nephron loss characteristic of the disease.

Unlike broad immunosuppressants, Sibeprenlimab is highly targeted. It selectively inhibits APRIL without affecting BAFF (B-cell activating factor), thereby avoiding severe, widespread lymphocyte depletion.

The clinical validation for Sibeprenlimab is largely driven by the pivotal Phase 3 VISIONARY study (NCT05248646), the largest IgAN clinical trial conducted to date.

The double-blind, placebo-controlled trial evaluated adults with biopsy-confirmed IgAN who were at high risk for disease progression despite receiving maximally tolerated standard-of-care therapies. Interim data published in the New England Journal of Medicine and presented at major 2025 nephrology congresses highlighted remarkable efficacy in reducing proteinuria—a key surrogate marker for kidney failure progression.

The safety profile of Sibeprenlimab proved highly favorable. The incidence of treatment-emergent adverse events (TEAEs) was actually slightly lower in the Sibeprenlimab group (76.3%) compared to the placebo group (84.5%), with the most common events being mild-to-moderate upper respiratory tract infections and injection site reactions.

Based on the overwhelming success of the VISIONARY trial's interim readouts, Sibeprenlimab was granted Accelerated Approval by the US FDA in November 2025 under the brand name VOYXACT®.

While the drug is now available for adult patients at risk of disease progression, the VISIONARY trial continues in a blinded manner to track the annualized slope of estimated glomerular filtration rate (eGFR) over 24 months. These final results, expected in 2026, will definitively confirm Sibeprenlimab's long-term ability to preserve kidney function and delay the onset of end-stage kidney disease (ESKD).

Are you investigating the APRIL signaling pathway, autoimmune kidney diseases, or novel MoAs in IgA Nephropathy? Don't wait on commercial drug sourcing. ichorbio offers a highly purified, research-grade Sibeprenlimab biosimilar ready to ship for your in vitro and in vivo preclinical studies. Manufactured to the highest standards for low endotoxin and high purity, our biosimilar provides the exact structural fidelity you need to generate reproducible, publication-ready data.